The global acromegaly and gigantism drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market includes the increasing prevalence of the pituitary tumors. Moreover, according to the American Cancer Society, around ten thousand pituitary tumors are diagnosed in America each year. Such a high prevalence rate of this tumor is one of the most important factors, which is augmenting the growth of the market. Furthermore, the rise in prevalence of other chronic disorders such as carney complex and McCune- Albright Syndrome is another factor that is expected to accelerate the growth of the global acromegaly and gigantism drugs market during the forecast period. However, the lack of awareness about the diagnosis and management of the disorder in many developing countries is the major restraining factor of the market.

Acromegaly is a rare hormonal disease that is caused due to excess production of growth hormone in adults. The condition of acromegaly is usually caused by a pituitary tumor. The term acro means extremities and megaly mean enlargement of; thus, acromegaly refers to enlargement of hands and feet. Gigantism is also a hormonal disorder that is caused due to excessive production of the growth hormone during childhood. The disorder is characterized by over bone growth and abnormal height. Acromegaly and gigantism are considered serious illnesses and are life-threatening. Acromegaly and gigantism is a rare disease and according to a journal, Pituitary, the total prevalence of acromegaly ranges from 2.8 to 13.7 cases per 1 lakh people each year. This, in turn, is driving the growth of the global acromegaly and gigantism drugs market.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Pfizer Inc., Novartis International AG, and Ionis Pharmaceuticals Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Acromegaly and Gigantism Drugs Market Report by Segment

By Type

    • Somatostatin Analogs

    • GH Receptor Antagonists

    • Dopamine Agonists

    • Recombinant Human IGF-1

By Application

    • Hospitals

    • Clinics

    • Others

Global Acromegaly and Gigantism Drugs Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa